Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to autoimmune and inflammatory diseases. Co.'s ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor, and a proliferation inducing ligand, cytokines, which play the roles in the activation, development, and survival of B cells. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and CD28 antagonist used for the treatment of autoimmune and inflammatory diseases. In immuno-oncology, Co.'s ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor used for the treatment of cancer. The ALPN average annual return since 2015 is shown above.
The Average Annual Return on the ALPN average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ALPN average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ALPN average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|